{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiawaobavymwzffd4inomvpppqcnedtut4yqp5lg2jx4dnyiujflr4",
    "uri": "at://did:plc:amgpmo7quvdl4rzvmmjibtx6/app.bsky.feed.post/3mf5gpcjqajt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreicofcjpxkktz6w4bbpqm3bgv24ioylp2ciinsg27tyvirwa3qxxgm"
    },
    "mimeType": "image/jpeg",
    "size": 598077
  },
  "path": "/2026/02/18/health/fda-moderna-flu-vaccine-mrna.html",
  "publishedAt": "2026-02-18T14:17:10.000Z",
  "site": "https://www.nytimes.com",
  "tags": [
    "Drugs (Pharmaceuticals)",
    "Vaccination and Immunization",
    "Regulation and Deregulation of Industry",
    "Influenza",
    "RNA (Ribonucleic Acid)",
    "Medicine and Health",
    "Coronavirus (2019-nCoV)",
    "Food and Drug Administration",
    "Moderna Inc",
    "Health and Human Services Department",
    "Kennedy, Robert F Jr"
  ],
  "textContent": "Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.",
  "title": "F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine"
}